Furtado RHM, et al. – Researchers investigated whether patients with type 2 diabetes mellitus and a previous myocardial infarction (MI) could derive even greater benefit from dapagliflozin in this subanalysis from the DECLARE-TIMI 58 Trial, which randomized patients with type 2 diabetes mellitus (n=17,160) and either established atherosclerotic cardiovascular disease (n=6,974) or multiple risk factors (n=10 186) to receive dapagliflozin or placebo. In all, the investigators noted a high risk of major adverse cardiovascular event (cardiovascular death, MI, or ischemic stroke) and cardiovascular death/hospitalization for heart failure in patients with type 2 diabetes mellitus and previous MI; a robust attenuation in the risk of both composite outcomes was achieved with dapagliflozin treatment in these patients.